» Articles » PMID: 31372695

Gastroprotective Effect of Cilostazol Against Ethanol- and Pylorus Ligation-induced Gastric Lesions in Rats

Overview
Specialty Pharmacology
Date 2019 Aug 3
PMID 31372695
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the availability of effective antiulcer medications, their suboptimal safety profile ignites the search for alternative/complementary treatments. Drug repositioning is an attractive, efficient, and low-risk strategy. Cilostazol, a clinically used phosphodiesterase 3 inhibitor, has pronounced anti-inflammatory and vasodilatory effects suggesting antiulcer activity. Using ethanol-induced and pyloric ligation-induced gastric ulcer models, we investigated the gastroprotective effect of cilostazol (5 or 10 mg/kg, p.o.) in comparison with the standard antiulcer ranitidine (50 mg/kg, p.o.) in rats. Gastric mucosa was examined macroscopically, histologically, and biochemically for ulcer severity, markers of oxidative stress, proinflammatory cytokines, apoptotic, and cytoprotective mediators. Gastric acidic output, peptic activity, and mucin content were measured in gastric fluids. Pretreatment with cilostazol reduced ulcer number and severity, ameliorated redox status (reduced glutathione and malonaldehyde content), and decreased levels of IL-1β, IL-6, and TNF-훼 in gastric mucosa, in parallel with increases in mucosal defensive factors nitric oxide (NO), prostaglandin E (PGE), and heat-shock protein 70 (HSP70) promoting mucus secretion, tissue perfusion, and regeneration. Histological examination confirmed the beneficial effects of cilostazol in terms of reducing focal necrosis and infiltration of inflammatory cells, as well as increasing mucopolysaccharide content. These beneficial effects are likely secondary to an increase in cAMP and decrease in apoptosis regulator Bcl-2-associated X protein (BAX). Cilostazol, in a dose-dependent effect, exhibited vasodilatory, anti-inflammatory, and antiapoptotic actions in the gastric mucosa resulting in significant antiulcer activity comparable with the standard drug, ranitidine, but devoid of antisecretory activity. Therefore, its use should be dose and ulcer-inducer dependent.

Citing Articles

In Vivo Gastroprotective Upshots of the Novel Schiff Base CdCl2 (C14H21N3O2) Compound by Bax/HSP-70 Signaling and Inflammatory Cytokines.

Shareef S Cureus. 2025; 16(12):e75963.

PMID: 39830532 PMC: 11741513. DOI: 10.7759/cureus.75963.


A bitter flavonoid gum from Dorema aucheri accelerate wound healing in rats: Involvement of Bax/HSP 70 and hydroxyprolin mechanisms.

Ahmed K, Jabbar A, Raouf M, Al-Qaaneh A, Mothana R, Alanzi A Skin Res Technol. 2024; 30(8):e13896.

PMID: 39128890 PMC: 11317193. DOI: 10.1111/srt.13896.


Cilostazol protects against gastric ulcers by regulating PPAR-γ, HO-1, PECAM-1, pErk-1, NF-κB, Bcl-2, and cleaved caspase-3 protein expression.

El-Shitany N, El-Saidy E, El-Naggar M, Sokar S Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):9033-9050.

PMID: 38884677 PMC: 11522149. DOI: 10.1007/s00210-024-03176-7.


Anti H. pylori, anti-secretory and gastroprotective effects of Thymus vulgaris on ethanol-induced gastric ulcer in Sprague Dawley rats.

Balaky S PLoS One. 2024; 19(1):e0287569.

PMID: 38271407 PMC: 10810472. DOI: 10.1371/journal.pone.0287569.


Mechanisms of anti-ulcer actions of (L.) in ethanol-induced gastric ulcer in rats.

Jabbar A, Mothana R, Abdulla M, Abdullah F, Ahmed K, Rizgar Hussen R Saudi Pharm J. 2023; 31(12):101850.

PMID: 37965491 PMC: 10641563. DOI: 10.1016/j.jsps.2023.101850.


References
1.
Bersimbaev R, Tairov M, Salganik R . Biochemical mechanisms of regulation of mucus secretion by prostaglandin E2 in rat gastric mucosa. Eur J Pharmacol. 1985; 115(2-3):259-66. DOI: 10.1016/0014-2999(85)90698-3. View

2.
Hollander D, Tarnawski A, Krause W, Gergely H . Protective effect of sucralfate against alcohol-induced gastric mucosal injury in the rat. Macroscopic, histologic, ultrastructural, and functional time sequence analysis. Gastroenterology. 1985; 88(1 Pt 2):366-74. DOI: 10.1016/s0016-5085(85)80191-8. View

3.
Bieber M, Schuhmann M, Volz J, Kumar G, Vaidya J, Nieswandt B . Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function. Stroke. 2018; 50(2):478-486. PMC: 6358218. DOI: 10.1161/STROKEAHA.118.023664. View

4.
Uchiyama S, Shinohara Y, Katayama Y, Yamaguchi T, Handa S, Matsuoka K . Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. Cerebrovasc Dis. 2014; 37(4):296-303. DOI: 10.1159/000360811. View

5.
Piper D . A comparative overview of the adverse effects of antiulcer drugs. Drug Saf. 1995; 12(2):120-38. DOI: 10.2165/00002018-199512020-00005. View